Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.47 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1320141 | 0.91 | PIK3CA (0.50) | SYKKMT2AHDAC6VSIRCYP3A4 | |
| SCHEMBL1318712 | 0.86 | HDAC6 (0.51) | SYKKMT2AHDAC6CYP3A4TSHR | |
| SCHEMBL1318576 | 0.85 | SYK (0.51) | SYKKMT2AHDAC6VSIRCYP3A4 | |
| SCHEMBL29381670 | 0.85 | SYK (0.51) | SYKKMT2AHDAC6VSIRCYP3A4 | |
| SCHEMBL7564159 | 0.81 | SYK (0.64) | SYKKMT2AHDAC6VSIRCYP3A4 | |
| SCHEMBL1319764 | 0.81 | SYK (0.48) | SYKKCNH3KMT2AHDAC6VSIR | |
| SCHEMBL22356493 | 0.79 | SYK (0.62) | SYKKMT2AHDAC6VSIRCYP3A4 | |
| SCHEMBL13955864 | 0.79 | KCNH3 (0.59) | KCNH3KMT2AMEN1 | |
| SCHEMBL27885824 | 0.78 | KCNH3 (0.52) | KCNH3KMT2AMEN1 | |
| SCHEMBL1320703 | 0.78 | SYK (0.48) | SYKKCNH3KMT2AHDAC6VSIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | claimed |
| US-8003645-B2 | type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives | BTG INTERNATIONAL LTD. (GB) | 2011-08-23 | — | — | US | claimed |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | claimed |
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | BTG INTERNATIONAL LTD. (GB) | 2005-03-10 | — | — | US | claimed |
| EP-1473289-A1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | Sankyo Company, Limited (JP) | 2004-11-03 | — | — | EP | claimed |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2011-11-10 | — | — | US | disclosed |
| US-8003645-B2 | type II diabetes; 6-Ethyl-N,N'-bis(3-hydroxyphenyl)-1,3,5-triazine-2,4-diamine; suppress the fall in MTT reduction capacity by beta -amyloid protein; inhibit impairment of long-term potentiation of hippocampal nerve cells, pyrimidine or 1,3,5 triazine derivatives | BTG INTERNATIONAL LTD. (GB) | 2011-08-23 | — | — | US | disclosed |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LTD. (GB) | 2009-11-19 | — | — | US | disclosed |
| US-7589105-B2 | For example, N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine, 2-methyl-N,N'-bis(3-hydroxyphenyl)pyrimidine-4,6-diamine | BTG INTERNATIONAL LIMITED (GB) | 2009-09-15 | — | — | US | disclosed |
| EP-1473289-B1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | BTG INT LTD (GB) | 2009-08-05 | — | — | EP | disclosed |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | BTG INTERNATIONAL LIMITED (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | BTG INTERNATIONAL LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1473289-A1 | PREVENTIVES OR REMEDIES FOR ALZHEIMER'S DISEASE OR AMYLOID PROTEIN FIBROSIS INHIBITORS CONTAINING NITROGEN-CONTAINING HETEROARYL COMPOUNDS | Sankyo Company, Limited (JP) | 2004-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054732-A1 | Preventives or remidies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds | NAT1, APP, BACE1 | SYK 3519/4885KCNH3 2126/4885KMT2A 3221/4885 |
| US-20110275641-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | SYK 2947/4885KCNH3 1645/4885KMT2A 2224/4885 |
| US-20090286794-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | SYK 2947/4885KCNH3 1645/4885KMT2A 2224/4885 |
| US-20090286809-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | SYK 2947/4885KCNH3 1645/4885KMT2A 2224/4885 |
| US-20080182846-A1 | Preventives or remedies for Alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | SYK 2947/4885KCNH3 1645/4885KMT2A 2224/4885 |
| US-20110275640-A1 | Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound | APP, BACE1, PSEN1 | SYK 2947/4885KCNH3 1645/4885KMT2A 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.